GLP-1s and the Heart: Mounjaro Cuts Attack Risk
Heart disease is the leading cause of death among people living with type 2 diabetes, and for years, managing one felt like negotiating with the other.
GLP-1s and the Heart: Mounjaro Cuts Attack Risk
There is a particular kind of dread that settles in after a type 2 diabetes diagnosis — not just the blood sugar monitoring and the medication schedules, but the cardiovascular shadow that follows quietly behind. Heart disease is the leading cause of death among people living with type 2 diabetes, and for years, managing one felt like negotiating with the other. New research is beginning to change that calculation in ways that feel genuinely significant.
A study examining the GLP-1 medication tirzepatide — sold as Mounjaro — found that people with type 2 diabetes who took it showed meaningfully reduced risk of heart attack compared to those on other glucose-lowering treatments. GLP-1 receptor agonists work by mimicking a hormone the gut releases after eating, signalling the pancreas to produce insulin and slowing the stomach's emptying. The weight reduction that follows gets most of the headlines. The cardiovascular effects are beginning to earn their own.
What's interesting about this particular research is the mechanism it points toward. The protection doesn't appear to come from weight loss alone. Tirzepatide seems to act on inflammation pathways and improve arterial function in ways that operate somewhat independently of the number on the scale. That distinction matters, because it suggests the drug is doing something more structural than simply helping people eat less.
The GLP-1 conversation has been loud for the past two years — Ozempic, Wegovy, Mounjaro rotating through every dinner party, every magazine, every comment thread. What gets lost in that noise is that these are serious medications with serious science behind them, and the research is still catching up to the enthusiasm. Most of the cardiovascular data so far comes from observational studies, which show association rather than cause. Randomised trials are ongoing.
What this means practically, if you or someone close to you has type 2 diabetes: the conversation with your doctor is worth having not just about blood sugar targets, but about cardiovascular risk explicitly. Ask which medications have cardiac outcome data. Ask where your numbers actually sit. The open pharmacies resource is useful if you need to access a pharmacist quickly for an initial conversation in Malta.
The one thing you can do: if you have type 2 diabetes and haven't had a cardiovascular risk assessment in the past year, book one. It takes twenty minutes and it tells you more than any headline can.
